Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

Etretinate has only moderate effects on localized scleroderma and lichen sclerosus.

Healthcare claims databases can help monitor drug safety, but may report adverse events differently than direct surveillance.

Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.

Baricitinib significantly improves hair regrowth in severe alopecia areata.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.

Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.

Baricitinib helps regrow hair in teens with severe alopecia areata.

Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.

Ixekizumab effectively treated severe psoriasis and hair loss in a patient.

Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.

Ritlecitinib works well and is safe for treating alopecia areata.

Tofacitinib taken by mouth helps treat hair loss in children.

Trapa bispinosa Roxb. extract may help reduce prostate size and cell growth in BPH.

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

JAK inhibitors show promise for treating various skin disorders effectively and safely.

RF-mesotherapy with bicalutamide may be a promising new treatment for hair loss.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

EF and PXE not closely related.

ITK inhibitors may effectively treat alopecia areata.

The new drug delivery system effectively targets lung cancer cells.

Dabrafenib can cause skin growths and sometimes low-grade skin cancer.

Epirubicin and cyclophosphamide cause more anemia and side effects than docetaxel and cyclophosphamide, but both are equally effective.

A new therapy for a skin blistering condition has not been developed yet.

Bendamustine combined with rituximab is an effective and well-tolerated treatment for certain types of lymphoma.

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

Near-infrared probes can safely and effectively image cysteine protease activity for disease diagnosis.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.